Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES vs CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.
Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.
Bowel cleansing prior to colonoscopy,Treatment of acute constipation in specific formulations
Bowel cleansing prior to colonoscopy,FDA-approved for bowel preparation in adults
4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.
Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.
Not applicable; PEG 3350 is not metabolized and is eliminated non-kinetically. Clinical effect occurs during colonic transit; residual drug cleared within 24–48 hours post-dose.
The terminal elimination half-life of the active metabolite BHPM is approximately 7-9 hours; clinical effect (bowel cleansing) begins within 1-3 hours and is complete by 6 hours.
Polyethylene glycol 3350 is not significantly metabolized; it is excreted unchanged in feces and urine. Electrolytes are absorbed and metabolized according to normal physiological pathways.
Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite. Magnesium and citrate are not metabolized; they are absorbed and excreted renally.
Primarily fecal (unchanged); minimal renal excretion (<2%) as intact polymer. Electrolytes absorbed and renally excreted.
Sodium picosulfate is primarily excreted in feces (90-95%) as the active metabolite BHPM via biliary elimination; <5% excreted renally. Magnesium oxide is excreted renally as magnesium ions. Citric acid is metabolized to bicarbonate and excreted renally.
PEG 3350: <1% bound to plasma proteins.
Sodium picosulfate and its active metabolite BHPM are minimally protein bound (<5%); magnesium oxide and citric acid are not significantly protein bound.
PEG 3350: 0.58 L/kg (confined to extracellular fluid; minimal tissue penetration).
The volume of distribution of the active metabolite BHPM is not well defined; magnesium distributes mainly to extracellular fluid (0.2-0.4 L/kg).
Oral: <0.06% for PEG 3350 (systemic absorption negligible). Electrolytes fully absorbed.
Sodium picosulfate is a prodrug; systemic bioavailability of BHPM after oral administration is approximately 10-15% due to extensive presystemic metabolism.
Contraindicated in patients with GFR < 30 m L/min/1.73 m² due to risk of electrolyte abnormalities and fluid overload. For GFR 30-60: use with caution, monitor electrolytes and volume status; consider split-dose regimen.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). For e GFR 30-60, use with caution and ensure adequate hydration.
No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to risk of electrolyte disturbances and fluid shifts.
No specific adjustment provided; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for electrolyte disturbances.
For colonoscopy: 4 L if ≥ 12 years old; for constipation: 0.5-1.5 g/kg/day (max 17 g/day) in children ≥ 6 months. Safety and efficacy not established for colonoscopy in children < 12 years; alternative polyethylene glycol products available.
Safety and efficacy not established in pediatric patients; not recommended for use in children.
Use with caution due to increased risk of electrolyte imbalance, aspiration, and fluid overload. Consider split-dose regimen, monitor renal function and electrolytes. Lower starting dose for constipation: 8.5 g daily.
No specific dose adjustment; ensure adequate hydration and monitor electrolyte levels due to increased risk of renal impairment and dehydration.
No FDA black box warning.
Risk of acute phosphate nephropathy and renal failure, particularly in patients at increased risk (e.g., renal impairment, dehydration, medications affecting renal function).
Risk of fluid and electrolyte abnormalities,Serious arrhythmias in patients with pre-existing electrolyte disturbances,Seizures,Renal impairment,Aspiration risk in patients with impaired gag reflex,Colonic mucosal ulcerations
Do not use in patients with gastrointestinal obstruction, perforation, or ileus.,Use caution in patients with renal impairment, electrolyte abnormalities, or those taking medications that affect electrolyte balance.,Monitor for fluid and electrolyte disturbances.,Avoid use in patients with known hypersensitivity to any component.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Known hypersensitivity to any component
Gastrointestinal obstruction, ileus, or perforation,Renal failure (creatinine clearance < 30 m L/min),Ascites,Congestive heart failure (NYHA class III or IV),Known hypersensitivity to any component
Avoid solid food during bowel preparation. Clear liquids only: water, clear broth, apple juice, white grape juice, black coffee or tea (no milk), clear sports drinks, gelatin without fruit. No red or purple colored liquids. Avoid alcohol.
Avoid solid food during bowel preparation. Consume only clear liquids (water, clear broth, apple juice, clear gelatin, black coffee or tea without milk, sports drinks). Avoid red, purple, or orange liquids that can be mistaken for blood during colonoscopy. Do not consume alcohol or dairy products.
Insufficient human data; animal studies not conducted. Use during pregnancy only if clearly needed. No known teratogenicity from limited reports.
No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbances from magnesium absorption may affect fetal development; avoid in first trimester if possible. Insufficient data for second and third trimesters; use only if clearly needed.
Excretion into breast milk unknown; polyethylene glycol is minimally absorbed systemically. Considered likely compatible with breastfeeding due to low absorption.
Unknown if components excreted in human milk. Sodium picosulfate may be excreted in small amounts; magnesium and citrate are normal milk constituents. Risk to infant considered low with single doses, but caution advised with chronic use. M/P ratio not available.
No dose adjustment required; pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety due to minimal systemic absorption.
No pharmacokinetic studies in pregnancy suggest dose adjustment. Use lowest effective dose and shortest duration. Avoid chronic use due to risk of electrolyte imbalances. Single-dose bowel preparation typical; no adjustment recommended.
Administer in divided doses to improve tolerance. Ensure adequate hydration to prevent electrolyte imbalance. Contraindicated in ileus, gastrointestinal obstruction, perforation, gastric retention, or toxic colitis. Use with caution in patients with impaired gag reflex to reduce aspiration risk. Monitor renal function and electrolytes in elderly or debilitated patients.
Ensure adequate hydration to prevent electrolyte disturbances. Monitor renal function and serum electrolytes, especially in elderly or patients with renal impairment. Administer as a split-dose regimen for optimal bowel cleansing. Avoid use in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease.
Take this medication exactly as prescribed for bowel preparation before colonoscopy.,Mix the powder with clear liquids as directed; do not consume any solid food during preparation.,Drink additional clear fluids throughout the preparation to stay hydrated.,Expect frequent, watery bowel movements; stay near a toilet.,If you experience severe abdominal pain, vomiting, or inability to pass stool, contact your doctor immediately.
Take this medication exactly as prescribed to prepare your colon for a procedure.,Drink plenty of clear liquids before, during, and after taking this medication to prevent dehydration.,You may experience bloating, cramping, or nausea; these are common and usually resolve after the bowel movement begins.,Do not take any other laxatives or stool softeners while using this product unless directed by your doctor.,Stop taking and contact your doctor if you experience severe abdominal pain, vomiting, or signs of an allergic reaction (rash, itching, swelling).,This medication will cause frequent, watery bowel movements; stay near a bathroom.
No interactions on record
"Amphetamine increases renal tubular pH, which reduces the excretion rate of magnesium oxide, potentially leading to elevated serum magnesium levels. This interaction may result in hypermagnesemia, manifesting as hypotension, respiratory depression, or cardiac arrhythmias, particularly in patients with renal impairment."
"Mesoridazine, a phenothiazine antipsychotic, can chelate with magnesium ions in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of magnesium oxide. This leads to diminished serum magnesium concentrations, potentially compromising magnesium's therapeutic effects for conditions such as hypomagnesemia or constipation. Clinically, patients may experience inadequate magnesium supplementation, risking exacerbation of electrolyte imbalances or reduced efficacy of magnesium-based therapies."
"Coadministration of magnesium oxide with rosuvastatin may decrease the serum concentration of rosuvastatin, potentially reducing its cholesterol-lowering efficacy. This interaction is thought to be due to chelation of the statin by magnesium ions in the gastrointestinal tract, impairing absorption. Clinically, this may lead to suboptimal lipid control and increased cardiovascular risk."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES vs CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE, answered by our medical review team.
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is a Bowel Evacuant that works by Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is a Laxative (Osmotic/Stimulant Combination) that works by Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES and CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is: 4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.. The standard adult dose of CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is: Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES and CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is classified as Category C. Insufficient human data; animal studies not conducted. Use during pregnancy only if clearly needed. No known teratogenicity from limited reports.. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is classified as Category C. No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbance. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.